Chicago—Although an alternate schedule of sunitinib (Sutent, Pfizer) in patients with metastatic renal cell carcinoma (mRCC) failed to reduce grade 3 or higher toxicity rates, the robust response rate and prolonged progression-free survival suggest the schedule has long-term tolerability, according to results presented at the 2017 annual meeting of the American Society of Clinical Oncology (abstract 4513).
Sunitinib is typically administered in a four-week-on, two-week-off (4/2) schedule,